SCHEMBL20178550

SCHEMBL20178550

CCCCCCC(C)c1ccc(C(=O)O)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
PLA2G4B P0C869 2/20 0.51
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA4 P22748 1/20 0.49
CA6 P23280 1/20 0.49
CA7 P43166 1/20 0.49
TPMT P51580 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
SMPD1 P17405 4/20 0.47
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
PTPN11 Q06124 1/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178566 0.88 MGLL (0.55) SMPD1
SCHEMBL11360410 0.87 THRA (0.45) TSHRPLA2G4BSMPD1
SCHEMBL20975508 0.83 TSHR (0.60) TSHRCA12CA1CA2CA4
SCHEMBL20178624 0.81 RARB (0.51) TSHRPLA2G4BTP53
SCHEMBL2586288 0.80 ACE2 (0.57) TSHRCA12CA1CA2CA4
SCHEMBL10587906 0.80 PTPN11 (0.47) TSHRPLA2G4BTP53ALDH1A1PTPN11
SCHEMBL24313204 0.79 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL1989676 0.78 TSHR (0.57) TSHRCA12CA1CA2CA4
Vanillic Acid SCHEMBL31550996 0.77 HTT (0.78) TSHRPLA2G4BCA12CA1CA2
SCHEMBL22210841 0.77 CA12 (0.43) TSHRCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 TSHR 320/4885PLA2G4B 2378/4885CA12 4171/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 TSHR 320/4885PLA2G4B 2378/4885CA12 4171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.